Advertisement
Research Article| Volume 306, ISSUE 1-2, P49-53, July 15, 2011

CHADS2 score is associated with 3-month clinical outcomes after intravenous rt-PA therapy in stroke patients with atrial fibrillation: SAMURAI rt-PA Registry

Published:April 15, 2011DOI:https://doi.org/10.1016/j.jns.2011.03.046

      Abstract

      Purpose

      The aim of this study was to examine whether CHADS2 score is associated with clinical outcomes following recombinant tissue type plasminogen activator (rt-PA) therapy in stroke patients with atrial fibrillation (AF).

      Methods

      We studied 218 consecutive stroke patients with AF [126 men, mean age 74.2 (SD 9.6) years] who received intravenous rt-PA therapy. CHADS2 score was calculated as follows: 2 points for prior ischemic stroke and 1 point for each of the following: age75 years, hypertension, diabetes, and congestive heart failure.

      Results

      Congestive heart failure was documented in 23 patients, hypertension in 138, age75 years in 116, diabetes in 35, and prior stroke in 35. The distribution of each CHADS2 score was: score of 0, 16.1% of patients; 1, 30.3%; 2, 29.4%; and 3 to 5, 24.3%. The median initial NIHSS score for each CHADS2 category was 12 (IQR 8–17), 16 (10–20), 14.5 (10–20.75), and 16 (11–21), respectively (p=0.168). Symptomatic ICH within the initial 36 h was found in 2.9%, 4.6%, 6.3%, and 0% of patients with each CHADS2 category, respectively. Cardiovascular events within 3 months occurred in 0%, 0%, 7.8% and 5.7%, respectively. Percentage of patients with chronic independence at 3 months corresponding to modified Rankin Scale2 was 57.1%, 45.5%, 31.3%, and 28.3%, respectively. Adjusted CHADS2 score was inversely associated with chronic independence (OR 0.72, 95% CI 0.55–0.93).

      Conclusion

      Lower CHADS2 score was associated with chronic independence at 3 months after intravenous rt-PA therapy in stroke patients with AF.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gage B.F.
        • Waterman A.D.
        • Shannon W.
        • Boechler M.
        • Rich M.W.
        • Radford M.J.
        Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
        JAMA. 2001; 285: 2864-2870
        • Gage B.F.
        • van Walraven C.
        • Pearce L.
        • Hart R.G.
        • Koudstaal P.J.
        • Boode B.S.
        • et al.
        Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
        Circulation. 2004; 110: 2287-2292
        • Healey J.S.
        • Hart R.G.
        • Pogue J.
        • Pfeffer M.A.
        • Hohnloser S.H.
        • De Caterina R.
        • et al.
        Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
        Stroke. 2008; 39: 1482-1486
        • Poli D.
        • Antonucci E.
        • Grifoni E.
        • Abbate R.
        • Gensini G.F.
        • Prisco D.
        Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention.
        Thromb Haemost. 2009; 101: 367-372
        • Hylek E.M.
        • Evans-Molina C.
        • Shea C.
        • Henault L.E.
        • Regan S.
        Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
        Circulation. 2007; 115: 2689-2696
        • Henriksson K.M.
        • Farahmand B.
        • Johansson S.
        • Asberg S.
        • Terent A.
        • Edvardsson N.
        Survival after stroke–the impact of CHADS2 score and atrial fibrillation.
        Int J Cardiol. 2009; 141: 18-23
        • Nakashima T.
        • Toyoda K.
        • Koga M.
        • Matsuoka H.
        • Nagatsuka K.
        • Takada T.
        • et al.
        Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke.
        Int J Stroke. 2009; 4: 425-431
        • Wahlgren N.
        • Ahmed N.
        • Eriksson N.
        • Aichner F.
        • Bluhmki E.
        • Davalos A.
        • et al.
        Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).
        Stroke. 2008; 39: 3316-3322
        • Kimura K.
        • Iguchi Y.
        • Shibazaki K.
        • Terasawa Y.
        • Inoue T.
        • Uemura J.
        • et al.
        Large ischemic lesions on diffusion-weighted imaging done before intravenous tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke.
        Stroke. 2008; 39: 2388-2391
        • Toyoda K.
        • Koga M.
        • Naganuma M.
        • Shiokawa Y.
        • Nakagawara J.
        • Furui E.
        • et al.
        Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register.
        Stroke. 2009; 40: 3591-3595
        • Nezu T.
        • Koga M.
        • Kimura K.
        • Shiokawa Y.
        • Nakagawara J.
        • Furui E.
        • et al.
        Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry.
        Neurology. 2010; 75: 555-561
        • Shinohara Y.
        • Yamaguchi T.
        Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision.
        Int J Stroke. 2008; 3: 55-62
      1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
        N Engl J Med. 1995; 333: 1581-1587
        • Yamaguchi T.
        • Mori E.
        • Minematsu K.
        • Nakagawara J.
        • Hashi K.
        • Saito I.
        • et al.
        Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
        Stroke. 2006; 37: 1810-1815
        • Mori E.
        • Minematsu K.
        • Nakagawara J.
        • Yamaguchi T.
        • Sasaki M.
        • Hirano T.
        Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II).
        Stroke. 2010; 41: 461-465
        • Nakagawara J.
        • Minematsu K.
        • Okada Y.
        • Tanahashi N.
        • Nagahiro S.
        • Mori E.
        • et al.
        Thrombolysis With 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS).
        Stroke. 2010; 41: 1984-1989
        • Davalos A.
        • Cendra E.
        • Teruel J.
        • Martinez M.
        • Genis D.
        Deteriorating ischemic stroke: risk factors and prognosis.
        Neurology. 1990; 40: 1865-1869
        • Jorgensen H.S.
        • Nakayama H.
        • Raaschou H.O.
        • Olsen T.S.
        Effect of blood pressure and diabetes on stroke in progression.
        Lancet. 1994; 344: 156-159
        • Weimar C.
        • Ziegler A.
        • Konig I.R.
        • Diener H.C.
        Predicting functional outcome and survival after acute ischemic stroke.
        J Neurol. 2002; 249: 888-895
        • Henon H.
        • Godefroy O.
        • Leys D.
        • Mounier-Vehier F.
        • Lucas C.
        • Rondepierre P.
        • et al.
        Early predictors of death and disability after acute cerebral ischemic event.
        Stroke. 1995; 26: 392-398
        • Johnston K.C.
        • Connors Jr., A.F.
        • Wagner D.P.
        • Knaus W.A.
        • Wang X.
        • Haley Jr., E.C.
        A predictive risk model for outcomes of ischemic stroke.
        Stroke. 2000; 31: 448-455
        • Thorvaldsen P.
        • Asplund K.
        • Kuulasmaa K.
        • Rajakangas A.M.
        • Schroll M.
        Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease.
        Stroke. 1995; 26: 361-367
        • Longstreth Jr., W.T.
        • Bernick C.
        • Fitzpatrick A.
        • Cushman M.
        • Knepper L.
        • Lima J.
        • et al.
        Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study.
        Neurology. 2001; 56: 368-375
        • Moroney J.T.
        • Bagiella E.
        • Paik M.C.
        • Sacco R.L.
        • Desmond D.W.
        Risk factors for early recurrence after ischemic stroke: the role of stroke syndrome and subtype.
        Stroke. 1998; 29: 2118-2124
        • Adams Jr., H.P.
        • Davis P.H.
        • Leira E.C.
        • Chang K.C.
        • Bendixen B.H.
        • Clarke W.R.
        • et al.
        Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
        Neurology. 1999; 53: 126-131
        • Leonardi-Bee J.
        • Bath P.M.
        • Phillips S.J.
        • Sandercock P.A.
        Blood pressure and clinical outcomes in the International Stroke Trial.
        Stroke. 2002; 33: 1315-1320
        • Loor H.I.
        • Groenier K.H.
        • Limburg M.
        • Schuling J.
        • Meyboom-de Jong B.
        Risks and causes of death in a community-based stroke population: 1 month and 3 years after stroke.
        Neuroepidemiology. 1999; 18: 75-84
        • Sacco R.L.
        • Shi T.
        • Zamanillo M.C.
        • Kargman D.E.
        Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study.
        Neurology. 1994; 44: 626-634
        • Sellars C.
        • Bowie L.
        • Bagg J.
        • Sweeney M.P.
        • Miller H.
        • Tilston J.
        • et al.
        Risk factors for chest infection in acute stroke: a prospective cohort study.
        Stroke. 2007; 38: 2284-2291
        • Ding R.
        • Logemann J.A.
        Pneumonia in stroke patients: a retrospective study.
        Dysphagia. 2000; 15: 51-57
        • Wahlgren N.
        • Ahmed N.
        • Davalos A.
        • Ford G.A.
        • Grond M.
        • Hacke W.
        • et al.
        Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.
        Lancet. 2007; 369: 275-282